In 2020, over 26.8 million people around the world were affected by opioid use disorder, with approximately 2.7 million cases of opioid use disorder in the United States alone. Since the beginning of the COVID-19 pandemic, rates of fentanyl use and opioid related overdoses nearly doubling. Effective medications for opioid use disorder (MOUD) have been well studied and have been shown to reduce opioid cravings, to reduce opioid use and to prevent opioid related deaths. Despite the availabilities of these MOUD, the medications are largely underutilized. Much of this lack is due to the many barriers to initiating MOUD treatment, including stigma, access to care, perception of strict oversight, and comorbid mental health issues. Shared decision making (SDM) in clinical practice involves making choices about a treatment plan through partnership between the clinician(s) and the patient. Decision-making tools can help encourage and guide SDM conversation. SDM has been found in initial studies to increase likelihood of MOUD induction. Despite these reports, only an estimated 23% of MOUD clinics invite patients into decision making processes. There are currently no validated SDM tools available to the public directed towards patients for MOUD initiation. Our study aimed to create a SDM tool for MOUD and to evaluate the feasibility and accessibility of this tool to patients and providers.